Since metformin was shown to interfere with the proliferation and clonal activity of AML cells without affecting normal CD34+ HSCs, numerous experiments have begun to further explore the anti-AML effects of metformin [240]. This evidence concerns the gene CD34 and acute myeloid leukemia.